IT1110460B
(it)
*
|
1977-03-02 |
1985-12-23 |
Ciba Geigy Ag |
Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
|
FR2639942B1
(fr)
*
|
1988-12-02 |
1991-03-29 |
Sanofi Sa |
Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
|
US5665756A
(en)
*
|
1994-08-03 |
1997-09-09 |
Hoechst Marion Roussel, Inc. |
Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
AU6776196A
(en)
*
|
1995-08-16 |
1997-03-12 |
Eli Lilly And Company |
Potentiation of serotonin response
|
IN182588B
(de)
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
IN186677B
(de)
|
1999-11-12 |
2001-10-20 |
Sun Pharmaceutical Ind Ltd |
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
US20080021085A1
(en)
*
|
2000-04-13 |
2008-01-24 |
Mayo Foundation For Medical Education And Research |
Method of reducing abeta42 and treating diseases
|
CA2405025A1
(en)
*
|
2000-04-24 |
2001-11-01 |
Aryx Therapeutics |
(2-aminoethyl) oxime derivatives for the treatment of depression
|
US7256191B2
(en)
*
|
2000-04-24 |
2007-08-14 |
Aryx Therapeutics |
Materials and methods for the treatment of depression
|
CN105712985A
(zh)
*
|
2001-10-12 |
2016-06-29 |
阿泽范药品公司 |
β-内酰胺后叶加压素V1a拮抗剂
|
AU2003217676B2
(en)
|
2002-02-22 |
2009-06-11 |
Takeda Pharmaceutical Company Limited |
Active agent delivery systems and methods for protecting and administering active agents
|
EP1603548A4
(de)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen
|
US20050042284A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Myriad Genetics, Incorporated |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
MXPA06002789A
(es)
|
2003-09-12 |
2006-06-14 |
Pfizer |
Combinaciones que comprenden ligandos alfa-2-delta.
|
EP1689721B1
(de)
*
|
2003-11-26 |
2010-07-14 |
Pfizer Products Inc. |
Aminopyrazolderivate als gsk-3-inhibitoren
|
EP1691811B1
(de)
|
2003-12-11 |
2014-07-23 |
Sunovion Pharmaceuticals Inc. |
Kombination aus einem sedativum und einem neurotransmitter-modulator und verfahren zur verbesserung der schlafqualität und zur behandlung von depression
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
EP1737473A4
(de)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
Lithium-kombinationen und relevante verwendungen
|
CN1946906A
(zh)
*
|
2004-04-29 |
2007-04-11 |
吉斯通护岸系统股份有限公司 |
用于墙、护墙和类似物的饰面
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US9597314B2
(en)
|
2005-03-22 |
2017-03-21 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
WO2006116150A1
(en)
|
2005-04-22 |
2006-11-02 |
Wyeth |
Dihydrobenzofuran derivatives and uses thereof
|
MX2007013179A
(es)
*
|
2005-04-22 |
2008-01-16 |
Wyeth Corp |
Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
|
EP1871358A1
(de)
|
2005-04-22 |
2008-01-02 |
Wyeth |
Benzofuranyl-alkanamin-derivate und deren verwendung als 5-ht2c-agonisten
|
BRPI0610037A2
(pt)
*
|
2005-04-22 |
2010-05-25 |
Wyeth Corp |
derivados de dihidrobenzofurano e uso dos mesmos
|
EP1904843A2
(de)
|
2005-07-08 |
2008-04-02 |
Braincells, Inc. |
Verfahren zur identifizierung von mitteln und zuständen für neurogenese-modulation
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
AU2006270039B2
(en)
|
2005-07-19 |
2013-07-04 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
|
CA2615063A1
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
CA2625153A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
EP1998773A2
(de)
*
|
2006-03-24 |
2008-12-10 |
Wyeth a Corporation of the State of Delaware |
Neue therapeutische kombinationen zur behandlung von depression
|
JP4615470B2
(ja)
*
|
2006-03-29 |
2011-01-19 |
卓郎 簑和田 |
大脳の認知力を用いた疾患治療・予防の方法および医薬
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
EP2377531A2
(de)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenese mittels Angiotensin-Modulation
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
EP2046119A2
(de)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Behandlung von psychiatrischen störungen
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
WO2008030651A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100016274A1
(en)
*
|
2006-09-14 |
2010-01-21 |
Koppel Gary A |
Beta-lactam cannabinoid receptor modulators
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
US20080171750A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation Of Neurogenesis With Use of Modafinil
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
JP5759470B2
(ja)
|
2009-10-23 |
2015-08-05 |
ヤンセン ファーマシューティカ エヌ.ベー. |
オレキシン受容体調節因子としての二置換オクタヒドロピロロ[3,4−c]ピロール
|
WO2011071995A2
(en)
|
2009-12-08 |
2011-06-16 |
Case Western Reserve University |
Compounds and methods of treating ocular disorders
|
CN103269584B
(zh)
|
2010-07-01 |
2017-05-03 |
阿泽凡药物公司 |
用于治疗创伤后应激障碍的方法
|
KR20140045925A
(ko)
|
2011-03-17 |
2014-04-17 |
루핀 리미티드 |
선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
|
KR101427221B1
(ko)
*
|
2012-08-29 |
2014-08-13 |
주식회사 에스텍파마 |
플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
|
EP2981518B1
(de)
*
|
2013-04-03 |
2021-03-03 |
ZCL Chemicals Ltd. |
Verbessertes verfahren zur herstellung von fluvoxaminmaleat
|
PL3104847T3
(pl)
|
2014-02-07 |
2021-07-05 |
Támogatott Kutatócsoportok Irodája |
Nowe zastosowanie związków agonistycznych receptora sigma-1
|
MX2016012645A
(es)
|
2014-03-28 |
2017-01-11 |
Azevan Pharmaceuticals Inc |
Composiciones y metodos para tratar enfermedades neurodegenerativas.
|
KR102559922B1
(ko)
|
2016-03-10 |
2023-07-25 |
얀센 파마슈티카 엔.브이. |
오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
|
ES2926179T3
(es)
|
2016-11-24 |
2022-10-24 |
Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag |
Utilización de composiciones para la conservación de órganos/tejidos
|
WO2019055913A1
(en)
|
2017-09-15 |
2019-03-21 |
Azevan Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
|
BR112022000992A2
(pt)
|
2019-07-19 |
2022-06-14 |
Arx Llc |
Regimes de tratamento de dexmedetomidina não sedantes
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|